{"schema_version":"secwatch.filing_event.v1","accession":"0001551152-25-000047","form_type":"8-K","ticker":"ABBV","cik":"0001551152","company_name":"AbbVie Inc.","filed_at":"2025-10-31T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.713173+00:00","generated_at":"2026-05-17T01:06:27.733119+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"AbbVie Q3 adjusted EPS $1.86 (down 38%), revenue up 9.1%; raises FY25 guidance; dividend up 5.5%","bullets":["GAAP diluted EPS $0.10 (down 88.6%); adjusted diluted EPS $1.86 (down 38%); includes $1.50/share unfavorable impact from acquired IPR&D.","Net revenues $15.776B, up 9.1% reported (8.4% operational); Immunology $7.885B (+11.9%) led by Skyrizi $4.708B (+46.8%).","Raises 2025 adjusted diluted EPS guidance to $10.61-$10.65 (from $10.38-$10.58); includes $2.05/share YTD IPR&D impact.","Quarterly dividend increased 5.5% to $1.73/share, payable Feb 17, 2026 to holders of record Jan 16, 2026.","Oncology $1.682B (-0.3%); Aesthetics $1.193B (-3.7%); Neuroscience $2.841B (+20.2%); Vraylar $934M, Botox Therapeutic $985M."],"urls":{"canonical":"https://secwatch.observer/filing/0001551152-25-000047","json":"https://secwatch.observer/filing/0001551152-25-000047.json","markdown":"https://secwatch.observer/filing/0001551152-25-000047.md","text":"https://secwatch.observer/filing/0001551152-25-000047.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1551152/000155115225000047/0001551152-25-000047-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1551152/000155115225000047/abbv-20251031.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T01:06:27.733119+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}